



Healthcare
Improvement
Scotland

SMC
Advice on new
medicines

www.scottishmedicines.org.uk

Statement of advice
SMC2972

lisocabtagene maraleucel dispersion for infusion (Breyanzi®)

Bristol Myers Squibb Pharmaceuticals Ltd

7 August 2026

ADVICE: in the absence of a submission from the holder of the marketing authorisation:

lisocabtagene maraleucel (Breyanzi®) is not recommended for use within NHSScotland.

Indication under review: treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), after two or more lines of systemic therapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair
Scottish Medicines Consortium